These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33343967)

  • 1. Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.
    Vaziri F; Colquhoun S; Wan YY
    Liver Res; 2020 Dec; 4(4):191-198. PubMed ID: 33343967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma.
    Shen S; Khatiwada S; Behary J; Kim R; Zekry A
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment.
    Spanu D; Pretta A; Lai E; Persano M; Donisi C; Mariani S; Dubois M; Migliari M; Saba G; Ziranu P; Pusceddu V; Puzzoni M; Astara G; Scartozzi M
    World J Hepatol; 2022 Jul; 14(7):1319-1332. PubMed ID: 36158925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
    Gok Yavuz B; Datar S; Chamseddine S; Mohamed YI; LaPelusa M; Lee SS; Hu ZI; Koay EJ; Tran Cao HS; Jalal PK; Daniel-MacDougall C; Hassan M; Duda DG; Amin HM; Kaseb AO
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Gut Microbiome and Hepatocellular Carcinoma: Implications for Early Diagnostic Biomarkers and Novel Therapies.
    Kang Y; Cai Y; Yang Y
    Liver Cancer; 2022 Apr; 11(2):113-125. PubMed ID: 35634424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review.
    Muscolino P; Granata B; Omero F; De Pasquale C; Campana S; Calabrò A; D'Anna F; Drommi F; Pezzino G; Cavaliere R; Ferlazzo G; Silvestris N; Speranza D
    Front Oncol; 2023; 13():1247614. PubMed ID: 37692859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research progress of gut microbiota in hepatocellular carcinoma.
    Li K; Liu J; Qin X
    J Clin Lab Anal; 2022 Jul; 36(7):e24512. PubMed ID: 35719048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention.
    Tian M; Shi Y; Liu W; Fan J
    Sci China Life Sci; 2019 Sep; 62(9):1138-1143. PubMed ID: 31119560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic approaches to hepatocellular carcinoma treatment.
    Miamen AG; Dong H; Roberts LR
    Liver Cancer; 2012 Nov; 1(3-4):226-37. PubMed ID: 24159587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
    Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
    Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
    Golonka RM; Vijay-Kumar M
    Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma.
    Qing X; Xu W; Zong J; Du X; Peng H; Zhang Y
    Biomark Res; 2021 Aug; 9(1):64. PubMed ID: 34419152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.
    Giglia JL; Antonia SJ; Berk LB; Bruno S; Dessureault S; Finkelstein SE
    Cancer Control; 2010 Apr; 17(2):120-9. PubMed ID: 20404795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Microbiome and Hepatocellular Carcinoma.
    Rattan P; Minacapelli CD; Rustgi V
    Liver Transpl; 2020 Oct; 26(10):1316-1327. PubMed ID: 32564483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
    Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
    J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.